The Motherisk Program, Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, Canada.
Reprod Toxicol. 2012 Nov;34(3):293-7. doi: 10.1016/j.reprotox.2012.04.015. Epub 2012 May 5.
An association between PPHN and antidepressant use in pregnancy has been reported.
We sought to examine this relationship.
A review of the literature was performed, to evaluate this association.
Six published studies fulfilled our criteria for inclusion, with only three studies large enough to have the power to detect an association. There appears to be a small but significantly, increased risk of late pregnancy SSRI exposure associated with PPHN in one case-control study; OR 5.1 (95% CI, 1.9-13.3) and two large cohort studies; RR 2.56; (95% CI, 1.17-4.85) and OR 2.1 (95% CI, 1.5-3.0) The other three studies did not find an association.
the absolute risk cannot be determined, but it is very small, probably less than 1%. If a pregnant woman requires pharmacological treatment, this information does not support discontinuation or lowering the dose of the antidepressant.
已有报道称，新生儿持续性肺动脉高压（PPHN）与孕妇使用抗抑郁药之间存在关联。
我们旨在探究这种关联。
我们对文献进行了综述，以评估这种关联性。
有 6 项已发表的研究符合纳入标准，但仅有 3 项研究的规模足以检测到这种关联。在一项病例对照研究中，SSRI 在妊娠晚期暴露似乎与 PPHN 有轻度但显著增加的风险相关；OR 5.1（95%CI，1.9-13.3），在两项大型队列研究中，RR 2.56（95%CI，1.17-4.85）和 OR 2.1（95%CI，1.5-3.0）。另外 3 项研究没有发现关联。
绝对风险无法确定，但风险非常小，可能低于 1%。如果孕妇需要药物治疗，这些信息并不支持停止或降低抗抑郁药的剂量。
